MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ
52.44
-0.75
-1.41%
After Hours: 52.31 -0.13 -0.25% 19:59 12/31 EST
OPEN
53.13
PREV CLOSE
53.19
HIGH
53.46
LOW
52.35
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
78.48
52 WEEK LOW
30.04
MARKET CAP
5.00B
P/E (TTM)
-9.3978
1D
5D
1M
3M
1Y
5Y
1D
ARK outperforms in 2025 With Tesla still Cathie Wood’s biggest bet
Seeking Alpha · 17h ago
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
Benzinga · 12/31/2025 22:06
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 12/29/2025 16:00
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Seeking Alpha · 12/29/2025 13:15
Weekly Report: what happened at CRSP last week (1222-1226)?
Weekly Report · 12/29/2025 10:24
Cathie Wood’s ARK Adds to CRISPR Stock — Here’s What Else It Traded This Week
TipRanks · 12/29/2025 06:12
Cathie Wood Adds to WeRide (WRD) and CRISPR, Trims Ibotta (IBTA) in Holiday Trades, 12/24/25
TipRanks · 12/25/2025 03:40
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
Seeking Alpha · 12/24/2025 17:48
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Webull offers Crispr Therapeutics AG stock information, including NASDAQ: CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.